A Silent Killer Claiming One Life Every 30 Seconds: What You Need to Know About Hepatitis Now

Viral hepatitis continues to claim approximately 1.3 million lives each year globally, making it one of the world's deadliest infectious diseases. Despite remarkable medical advances, this silent killer affects over 300 million people worldwide, with many unaware they're infected until serious liver damage occurs.

What Makes 2025 a Turning Point for Hepatitis Treatment?

This year marks significant breakthroughs in hepatitis care that could change everything. The Food and Drug Administration (FDA) granted Breakthrough Therapy designation to brelovitug for chronic hepatitis D, showing 100% virologic response in phase 2 trials. Meanwhile, glecaprevir/pibrentasvir became the first treatment approved for acute hepatitis C, offering an 8-week cure with a 96% success rate.

Global hepatitis B vaccine coverage has surpassed the critical 90% threshold, and between 2014 and 2023, an estimated 12.7 million hepatitis C patients received direct-acting antivirals (DAAs) treatment. These medications have revolutionized hepatitis C care, with cure rates exceeding 95%.

Why Are So Many Cases Still Going Undiagnosed?

The biggest challenge remains detection. Only 13% of chronic hepatitis B cases worldwide had received a diagnosis as of 2022, while merely 36% of hepatitis C cases were identified between 2015 and 2022. This represents a massive gap from the 2030 target of 90% diagnosis rates.

Emergency departments offer a promising solution for catching more cases. A recent study called DETECT Hep C found that non-targeted screening (testing all eligible patients) identified 154 new hepatitis C diagnoses compared to 115 found through targeted screening (testing only high-risk patients) across three urban emergency departments.

However, the study revealed concerning gaps in the care process:

• Linkage to Care: Only 20% of diagnosed patients connected with ongoing medical care within 18 months
• Treatment Initiation: Just 16% of diagnosed patients actually started hepatitis C treatment
• Treatment Completion: Only 12% completed their full course of therapy

What Barriers Still Stand in the Way?

The World Health Organization's 2025 theme "Hepatitis: Let's Break It Down" highlights the urgent need to dismantle financial, social, and systemic barriers that prevent hepatitis elimination. Low-income countries face particularly severe diagnostic capacity constraints, with advanced testing like polymerase chain reaction (PCR) often unavailable.

Treatment costs have dropped significantly, with direct-acting antivirals now costing $75 per capita in low- and middle-income countries. However, access remains uneven globally, with over 85% of hepatitis-related deaths occurring in low- and middle-income countries.

A controversial policy change has also sparked concern among healthcare providers. In December 2025, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted to recommend individual-based decision-making for hepatitis B vaccination in infants born to mothers who test negative for the virus, moving away from universal vaccination.

Despite these challenges, progress continues. Egypt became the first country to receive World Health Organization elimination certification in 2024, proving that hepatitis elimination is achievable. High-sensitivity point-of-care testing tools are making screening more accessible in primary care settings, while multiple countries have implemented comprehensive national hepatitis registries to track progress toward the 2030 elimination goals.